Barbara G. Kravitz

4.9k total citations · 1 hit paper
23 papers, 3.6k citations indexed

About

Barbara G. Kravitz is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Epidemiology. According to data from OpenAlex, Barbara G. Kravitz has authored 23 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 14 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Epidemiology. Recurrent topics in Barbara G. Kravitz's work include Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (10 papers) and Peroxisome Proliferator-Activated Receptors (8 papers). Barbara G. Kravitz is often cited by papers focused on Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (10 papers) and Peroxisome Proliferator-Activated Receptors (8 papers). Barbara G. Kravitz collaborates with scholars based in United States, Canada and United Kingdom. Barbara G. Kravitz's co-authors include Steven E. Kahn, Giancarlo Viberti, Bernard Zinman, William H. Herman, Steven M. Haffner, Rury R. Holman, John M. Lachin, Mark Heise, Nigel C. Jones and Mark O’Neill and has published in prestigious journals such as New England Journal of Medicine, Circulation and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Barbara G. Kravitz

21 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

2006 2.2k citations Steven E. Kahn, Steven M. Haffner et al. New England Journal of Medicine profile →

Peers

Barbara G. Kravitz

EDM

SURGE

ONCOL

PHYSI

Mark Heise United States

Mark O’Neill United Kingdom

Riccardo Candido Italy

Yong‐Ki Min South Korea

Annette Mathisen United States

Christos Tikellis Australia

James F. List United States

Martin Ridderstråle Sweden

Itamar Raz United States

Sally M. Marshall United Kingdom

Mark Heise United States

Barbara G. Kravitz

2.6k ×1.1

EDM

2.0k ×1.0

936 ×1.0

SURGE

308 ×0.8

ONCOL

346 ×0.9

PHYSI

Citations per year, relative to Barbara G. Kravitz Barbara G. Kravitz (= 1×) peers Mark Heise

Countries citing papers authored by Barbara G. Kravitz

Since Specialization

Citations

This map shows the geographic impact of Barbara G. Kravitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara G. Kravitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara G. Kravitz more than expected).

Fields of papers citing papers by Barbara G. Kravitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara G. Kravitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara G. Kravitz. The network helps show where Barbara G. Kravitz may publish in the future.

Co-authorship network of co-authors of Barbara G. Kravitz

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara G. Kravitz. A scholar is included among the top collaborators of Barbara G. Kravitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara G. Kravitz. Barbara G. Kravitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chung, Yoon‐Sok, Dong Jin Chung, Moo-Il Kang, et al.. (2016). Vitamin D Repletion in Korean Postmenopausal Women with Osteoporosis. Yonsei Medical Journal. 57(4). 923–923. 8 indexed citations

Koh, Jung‐Min, Dong Jin Chung, Yoon‐Sok Chung, et al.. (2016). Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension. Yonsei Medical Journal. 57(4). 905–905. 19 indexed citations

Lachin, John M., Giancarlo Viberti, Bernard Zinman, et al.. (2011). Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy. Clinical Journal of the American Society of Nephrology. 6(5). 1032–1040. 65 indexed citations

García‐García, Héctor M., Scot Garg, Salvatore Brugaletta, et al.. (2011). Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history). International journal of cardiac imaging. 28(3). 455–465. 11 indexed citations

Kahn, Steven E., John M. Lachin, Bernard Zinman, et al.. (2011). Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT. Diabetes. 60(5). 1552–1560. 180 indexed citations

Gerstein, Hertzel C., Robert E. Ratner, Christopher P. Cannon, et al.. (2010). Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation. 121(10). 1176–1187. 69 indexed citations

Zinman, Bernard, Steven M. Haffner, William H. Herman, et al.. (2009). Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 95(1). 134–142. 148 indexed citations

Kahn, Steven E., Steven M. Haffner, Giancarlo Viberti, et al.. (2009). Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain. Diabetes Care. 33(1). 177–183. 30 indexed citations

Ratner, Robert E., Christopher P. Cannon, Hertzel C. Gerstein, et al.. (2008). Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics. American Heart Journal. 156(6). 1074–1079. 14 indexed citations

10.

Kahn, Steven E., Bernard Zinman, John M. Lachin, et al.. (2008). Rosiglitazone-Associated Fractures in Type 2 Diabetes. Diabetes Care. 31(5). 845–851. 411 indexed citations

11.

Haffner, S M, Steven E. Kahn, B. Zinman, et al.. (2007). Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain. Diabetologia. 50. 2 indexed citations

12.

Kahn, Steven E., Steven M. Haffner, Mark Heise, et al.. (2006). Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. New England Journal of Medicine. 355(23). 2427–2443. 2202 indexed citations breakdown →

13.

Viberti, Giancarlo, John M. Lachin, Rury R. Holman, et al.. (2006). A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabetic Medicine. 23(12). 1289–1294. 35 indexed citations

14.

Rosenstock, Julio, B. J. Goldstein, A Vinik, et al.. (2005). Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obesity and Metabolism. 8(1). 49–57. 52 indexed citations

15.

Herman, WH, et al.. (2005). PDB21 HEALTH CARE RESOURCE UTILIZATION AND COST IN TYPE-2 DIABETES PATIENTS RECEIVING COMBINATION SULFONYLUREA (SU) AND ROSIGLITAZONE (RSG): THE RESULT TRIAL. Value in Health. 8(3). 358–358.

16.

Herman, WH, et al.. (2005). Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.. PubMed. 11(4). 273–8. 13 indexed citations

17.

Fleischer, Arthur C., et al.. (2001). An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms. American Journal of Obstetrics and Gynecology. 184(2). 70–74. 63 indexed citations

18.

Fleischer, Arthur C., James E. Wheeler, I‐Tien Yeh, et al.. (1999). Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene.. Journal of Ultrasound in Medicine. 18(7). 503–512. 42 indexed citations

19.

Fleischer, Arthur C., James E. Wheeler, Barbara G. Kravitz, & Brian MacDonald. (1998). P-57. Endometrial Assessment in Osteopenic Post-menopausal Women Treated with Idoxifene. Menopause The Journal of The North American Menopause Society. 5(4). 272–272. 1 indexed citations

20.

Meltzer, Eric B., et al.. (1967). A new look at ventricular tachycardia.. PubMed. 22(6). 519–35. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact